enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · IEX Real-Time Price · USD
5.70
+0.04 (0.71%)
Jul 22, 2024, 9:55 AM EDT - Market open
enVVeno Medical Employees
enVVeno Medical had 31 employees as of December 31, 2023. The number of employees increased by 1 or 3.33% compared to the previous year.
Employees
31
Change (1Y)
1
Growth (1Y)
3.33%
Revenue / Employee
n/a
Profits / Employee
-$713,419
Market Cap
77.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
SHL Telemedicine | 583 |
MDxHealth | 300 |
Eagle Pharmaceuticals | 134 |
Theratechnologies | 103 |
Kronos Bio | 63 |
Spero Therapeutics | 46 |
Ovid Therapeutics | 40 |
Cognition Therapeutics | 28 |
NVNO News
- 3 years ago - Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann - Accesswire
- 3 years ago - Hancock Jaffe To Rebrand As enVVeno Medical - Benzinga
- 3 years ago - Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs - Accesswire
- 3 years ago - Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021 - Accesswire
- 3 years ago - Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules - Accesswire
- 3 years ago - Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve - Benzinga
- 3 years ago - Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting - Accesswire
- 3 years ago - Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device - Benzinga